Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $76.00 at Bank of America

Keros Therapeutics (NASDAQ:KROS) had its target price reduced by Bank of America from $81.00 to $76.00 in a report issued on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts also recently weighed in on the company. Oppenheimer began coverage on Keros Therapeutics in a research report on Tuesday, June 25th. They issued an outperform rating and a $102.00 target price for the company. Truist Financial restated a buy rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, HC Wainwright reiterated a buy rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of Buy and an average target price of $89.86.

Keros Therapeutics Stock Up 1.0 %

KROS stock opened at $56.98 on Thursday. Keros Therapeutics has a 52-week low of $27.02 and a 52-week high of $73.00. The business has a fifty day moving average of $48.35 and a two-hundred day moving average of $53.49. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -11.06 and a beta of 1.22.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The company had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter in the prior year, the firm earned ($1.27) earnings per share. As a group, sell-side analysts anticipate that Keros Therapeutics will post -4.78 EPS for the current year.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the transaction, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Keros Therapeutics by 7.9% in the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after acquiring an additional 113,563 shares in the last quarter. Darwin Global Management Ltd. lifted its holdings in shares of Keros Therapeutics by 6.3% in the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after purchasing an additional 89,952 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after purchasing an additional 176,803 shares during the period. Franklin Resources Inc. grew its stake in Keros Therapeutics by 47.9% during the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after buying an additional 226,674 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Keros Therapeutics during the fourth quarter worth approximately $27,367,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.